摘要
单克隆抗体（ 单抗） 对相应的抗原有高度特异性。因此，利用单抗作为治疗剂或利用单抗作为特异性载体制成导向药物（ 免疫偶联物） ，对于治疗肿瘤有巨大潜力和引人瞩目的前景。大量研究证明，单抗导向药物对肿瘤靶细胞有选择性杀伤作用，显示特异性结合和内化；在动物体内显示肿瘤特异性分布以及更高的疗效。单抗与单抗导向药物在人体应用面临一些免疫学和药理学的问题。当前研究的发展趋向是单抗人源化，偶联物小型化与偶联物高效化。近两年来关于单抗治疗肿瘤课题受到更大关注，再度成为医药生物技术领域的热点。
Monoclonal antibody(McAb)is highly specific to its antigen.Therefore,it is highly attractive to explore the possible use of McAb and its conjugate,immunoconjugate,for cancer treatment.A series of studies have shown that McAb immunoconjugates exert selective cytotoxicity against cancer target cells,display specific binding and internalization in cancer cells;furthermore,McAb and immunoconjugates display tumor specific distribution and higher therapeutic efficacy in animal experiments.However,there are immunological and pharmacological obstacles when McAb and immunoconjugates enter clinical trial.Recent approaches include the humanization of antibody,downsizing of the conjugate molecule,and increasing the potency of cytotoxicity.The study of McAb therapeutics for cancer has drawn much more attention,particularly in recent two years.This has become the hot topic again in the field of biotechnology medicines.
出处
《世界科技研究与发展》
CSCD
1999年第5期5-7,8,共4页
World Sci-Tech R&D
